Here's why the Incannex (ASX:IHL) share price is up 10% today.

The Incannex (ASX:IHL) share price is flying today after the company's new drug delivered positive results in its latest clinical trial.

| More on:
Young doctor raising arms in air with hands in fists celebrating a new development

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Incannex Healthcare Ltd (ASX: IHL) shares are up again today as the company announced its new CBD-based drug is more effective in treating rheumatoid arthritis than currently available medications.

The Incannex share price opened nearly 15% higher than yesterday's close after the news broke. It has since dropped back to 22.5 cents, representing a 9.76% gain for the day so far. 

Incannex is a pharmaceutical development company working on the commercialisation of medical cannabis and psychedelic medicine therapies.

Here's a closer look at what the company announced today.

Rheumatoid arthritis treatment breakthrough

The Incannex share price is surging higher today after the company heralded another research program for its new drug IHL-675A following positive results in a pre-clinical study. 

The company's latest study found the drug is up to 3.5 times more effective at reducing arthritis than common treatments currently on market.

Currently, the main treatment for rheumatoid arthritis is hydroxychloroquine (HCQ), marketed as Plaquenil. The company noted long term use of HCQ has been linked to increased cardiovascular mortality.

Incannex's new treatment is a combination of cannabidiol (CBD) and HCQ. By combining CBD And HCQ, the amount of HCQ needed to treat arthritis can be reduced up to 10-fold, resulting in fewer side effects for patients.

In further news boosting the Incannex share price, the new drug also showed potential for treating other types of inflammation. The study demonstrated it to have "potent anti-inflammatory activity" when treating inflammatory lung conditions such as asthma and bronchitis, as well as colitis.

Incannex plans to market IHL-675A in key global markets, including the United States, Europe, Japan and Israel. It has filed an International Patent Application and plans to pursue US Food and Drug Administration registration, subject to the ongoing success of clinical trials. 

Commentary from management

Incannex Healthcare CEO and managing director Joel Latham said IHL-675A has the potential to be a breakthrough in the treatment of rheumatoid arthritis. He commented:

Hydroxychloroquine is an established medication for rheumatoid arthritis and IHL-675A has been demonstrated to outperform it at reducing disease severity in an animal model.

The benefit of the CBD and hydroxychloroquine combination in IHL-675A is potent. The observation that IHL-675A was as effective or better than a standard dose of hydroxychloroquine, even though it contained 90% less drug, is an exciting result for the Company.

Incannex share price snapshot

Over the past 12 months, the Incannex share price has risen by more than 460%. The company's shares are also up by 50% year to date.

Based on the current Incannex share price, the company has a market capitalisation of around $217 million with approximately 1 billion shares outstanding.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Market News

A happy young couple lie on a wooden deck using a skateboard for a pillow.
Share Gainers

These were the best-performing ASX 200 shares in March

These shares made their shareholders smile in March thanks to some very big gains.

Read more »

Businessman using a digital tablet with a graphical chart, symbolising the stock market.
Opinions

2 ASX shares I have been buying in 2024!

I’m a believer in the long-term outlook of these stocks.

Read more »

Stock market chart in green with a rising arrow symbolising a rising share price.
Share Gainers

Here are the top 10 ASX 200 shares today

It was a massive day for the ASX 200, with a new all-time high recorded.

Read more »

A man sits thoughtfully on the couch with a laptop on his lap.
Technology Shares

This ASX tech stock rocketed 60% in March! Can it keep on delivering?

After soaring in March, the ASX tech stock is now up 169% since this time last year.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man clasps his hand to his head with his eyes closed and a pained expression on his face as he clasps a laptop computer in front of him, seemingly learning of bad news or a poor investment.
Share Fallers

Why Burgundy Diamond Mines, Clarity Pharmaceuticals, EML, and Zip are sinking today

These ASX shares are ending the week in the red. But why?

Read more »

A young women pumps her fists in excitement after seeing some good news on her laptop.
Share Gainers

Why Mesoblast, Newmont, Pilbara Minerals, and Platinum shares are jumping

These ASX shares are ending the week strongly. But why?

Read more »

a young boy dressed up in a business suit and tie has a cute grin and holds two fingers up.
Opinions

2 of my top ASX 200 shares to consider buying before April

I would happily exchange dollars for these two shares right now.

Read more »